Ticker Symbol: ADVM
Adverum Biotechnologies Inc
$2.15 - 20-11-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001501756
Company Profile
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 800 Saginaw Drive
Website: https://adverum.com/
CEO: Leone Patterson
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 20, 2023 03:30 PM EST
Previous Close: $0.96
Change:
$0.07
(
8.14%)
Days Range: $0.89 - $1.02
Beta: 0.68
52wk. High: $2.34
52wk. Low: $0.53
Ytd. Change 73.85%
50 Day Moving Average: $1.37
200 Day Moving Average: $1.40
Shares Outstanding: 100993010
Valuation
Market Cap: 9.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A